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• Vulvar melanoma is a rare gynaecological cancer with poor prognosis due to its high metastatic potential.
• The only potentially curative option for localized disease is complete surgical resection with negative margins.
• Sentinel lymph node biopsy is only recommended in order to direct adjuvant treatment.
• Analysis for targetable mutations should be incorporated into routine clinical testing for vulvar melanoma.
• Immunotherapy with anti-PD1 or anti-CTLA4 should be considered in metastatic or non-resectable vulvar melanoma.⁎ Corresponding author at: Department of Gynecology,
E-mail address: f.l.boer@lumc.nl (F.L. Boer).
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Available online xxxxObjective. To identify clinicopathological characteristics, treatment patterns, clinical outcomes and prognostic
factors in patients with vulvar melanoma (VM).
Materials & methods. This retrospective multicentre cohort study included 198 women with VM treated in
eight cancer centres in the Netherlands and UK between 1990 and 2017. Clinicopathological features, treatment,
recurrence, and survival data were collected. Overall and recurrence-free survival was estimated with the
Kaplan-Meier method. Prognostic parameters were identified with multivariable Cox regression analysis.
Results. Themajority of patients (75.8%) had localized disease at diagnosis. VMwas significantly associated
withhigh-riskclinicopathological features, includingage,tumourthickness,ulceration,positiveresectionmargins
and involved lymphnodes. Overall survival was 48% (95% CI 40–56%) and 31% (95% CI 23–39%) after 2 and 5 years
respectively and did not improve in patients diagnosed after 2010 compared to patients diagnosed between
1990and2009.Recurrenceoccurred in66.7%ofpatients, ofwhich two-thirdwasnon-local. Inmultivariable anal-
ysis,ageandtumoursizewereindependentprognosticfactors forworsesurvival.Prognostic factors forrecurrence
were tumoursizeand tumour type.Only theminorityofpatientswere treatedwith immuno-or targeted therapy.
Conclusion.Our results show that even clinically early-stage VM is an aggressive disease associatedwith poor
clinical outcome due to distant metastases. Further investigation into the genomic landscape and the immune
microenvironment in VMmay pave theway to novel therapies to improve clinical outcomes in these aggressive
tumours. Clinical trials with immunotherapy or targeted therapy in patients with high-risk, advanced or meta-
static disease are highly needed.






RecurrenceLeiden University Medical Centre, P.O. Box 9600, 2300, RC, Leiden, the Netherlands.
d equally to this article.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Eikelder, N. vanGeloven, et al., Evaluation of treatment, prognostic factors, and survival in 198 vulvar
Oncology, https://doi.org/10.1016/j.ygyno.2021.01.018
F.L. Boer, M.L.G. ten Eikelder, N. van Geloven et al. Gynecologic Oncology xxx (xxxx) xxx1. Introduction
Mucosalmelanomas (MM)are a rareclinical entity andcomprise less
than 2% of totalmelanomas. [1] PrimaryMMarise frommelanocytes lo-
cated inmucosalmembranes lining the respiratory, gastrointestinal and
urogenital tract. Compared with cutaneous melanomas (CM) (80%),
MMhave a poor five-year survival of only 25%. [2] About 18–40% ofMM
originate fromthevulvarregion.[3]Vulvarmelanoma(VM)is thesecond
most commonmalignancy of the vulva, after squamous cell carcinoma,
but is still rarewith an incidence of 0.1 per 100,000 females per year. [4]
AlthoughVMarisesonthehairyandglabrousskinof thevulva, it ismostly
described asMMdue to its location and continuitywith vaginalmucosa.
[5,6] Because of the low incidence of VM, large studies are scarce and
treatment of the disease remains difficult. Recurrence rates lie between
42 and 70%, with a reported disease-free survival ranging between 12
and 63months. [5] The reported 5-year survival rates vary between 24%
and 79%. [5]Mostwomen diagnosedwith VM are postmenopausal and
presentation is usually delayed due to the anatomic locationwhich con-
tributes to the poor prognosis. [5,7]
Surgical treatment in the vulvar area and a high risk of recurrent dis-
ease present major clinical challenges in the treatment of patients with
VM. [8] Clinical guidelines for VMhave been based on evidence and rec-
ommendations for CM. [9] In addition, gynaecologic oncologists who
treat VM, are influenced by the surgical management principles for
the more common squamous cell carcinoma of the vulva. Therefore,
consensus guidelines regarding type of surgery, optimal surgical mar-
gins, groin treatment and adjuvant therapy for VM, do not exist.
The introduction of effective immune- and targeted therapies in
2011 has significantly improved survival in advanced CM, however,
the prognosis of patients with advanced MM has not changed. [10] A
possible explanation might be the pathogenesis of MM, which seems
to differ from that of cutaneous melanoma. [11,12] It has been shown
that MM have a different molecular signature than CM by lacking
BRAF and NRAS mutations and harbouring KIT mutations. [13–15] KIT
mutations were shown to be the highest in VM (22%) compared with
other MM subtypes (8.8%). [14] So far only a few studies describe treat-
ment outcomes of immune- and targeted therapy in VM.
The identification of clinicopathological characteristics and prognos-
tic factors is important to develop clinical guidelines and define patients
who may benefit from adjuvant or novel treatments. It remains uncer-
tain whether the poor prognosis of VM is due to the usually more
progressed disease at initial diagnosis or to the biologically more ag-
gressive behaviour. Until now, prognostic factors in VM are not well
established and most studies included small patient numbers.
The aim of this studywas to investigate the clinicopathological char-
acteristics in relation to clinical outcome, survival and recurrence rates
in a large cohort of patients with VM treated in melanoma referral cen-
tres in the Netherlands and UK over a 27-year period. Furthermore, we
summarized treatment outcomes in patients who received immune-
and targeted therapies.
2. Methods
2.1. Study design and patients
A retrospective evaluation of patients diagnosedwith primary VM at
five academic medical centers in the Netherlands and three melanoma
treatment hospitals in the UK was performed. Clinical, histopathologi-
cal, and treatment data of all patients diagnosed between January
1990 and December 2017 in the Netherlands and between January
2000 and December 2017 in the UKwere obtained from themedical re-
cords. This study was approved by the Dutch medical ethics committee
(reference number G18.046) and HRA (Health Research Authority) in
the UK (REC reference 19/HRA/0070). Data collection and storage was
carried out according to the guidelines of the ethics committees of the
corresponding hospitals.2
2.2. Clinical and histopathological characteristics and treatment outcomes
Inclusion criteria were pathologically confirmed primary VM and
age ≥ 18 years. Patients of whom clinical data or pathology reports
were missing were excluded from this study.
Patient demographics including age at diagnosis, primary tumour
characteristics, treatment details, adjuvant therapy, the site and date of
any recurrences ormetastases, and follow up data were obtained from
all patients. Adjuvant treatment included re-excision, radiotherapy, che-
motherapy, immunotherapy or targeted therapy. For patients treated
with immune- or targeted therapy, the best overall response rate
(BORR)was defined following the RECIST 1.1 guideline. [16] Recurrence
was defined as a pathologically or radiologically confirmed recurrence
after a disease-free period. Local recurrence was defined as any recur-
rence on the vulva and a regional recurrence was defined as lymph
nodemetastasis inthegroin(s).Locoregionalrecurrencereferstoconcur-
rent local andgroin recurrence.Distant recurrencewasdefinedasanyre-
current disease beyond the vulva or the groins with or without the
presence of a local or regional recurrence. Date of last follow-upwas de-
fined as the last contactwith a gynaecologist or oncologist or the date of
death. Follow-upwas completed until December 2019.
Histopathologicaldatathatwerecollectedfromthepathologyreports
included tumour type, tumour size, tumour thickness (Breslow), ulcera-
tion,mitoticactivity,microsatellosis, regressivechanges, angiolymphatic
involvement,margin status, lymphnode involvement andmutation sta-
tus (BRAF, cKIT, NRAS, GNAQ). All patients were classified according to
the AJCC version 2009 (7th edition) staging system (S1) [17] Since this
is a retrospective study, all cases before 2009 have been re-classified ac-
cording to this staging system.
2.3. Statistical analysis
Normally distributed continuous data were reported as means with
standard deviations and skewed distributions as medians with inter-
quartile ranges. Percentage calculation was based on the number of
available observations. Differences between descriptive variables were
tested with the Chi-square test, the Fisher's exact test, the independent
t-test or the Mann-Whitney U test.
Overall survival (OS) percentages were derived from the analysis of
the time in months from the date of initial diagnosis until death or last
follow-up. Recurrence-free survival (RFS) percentages were derived
from the analysis of the time inmonths from the date of initial diagnosis
until recurrence or last follow-up. OS and RFS were calculated and plot-
ted using KaplanMeier analysis. The log rank test was used to compare
OS and RFS between the groups. Prognostic factors for OS and RFS were
identified with univariable andmultivariable analysis using Cox regres-
sion analysis. Univariate preselection of variables was used to build a
multivariable model for overall and recurrence-free survival. To deal
with missing data of possible predictors, we imputed for data used in
the multivariable cox regression analysis, which were assumed to be
missing ‘at random’. Missing covariates for the Cox regression model
were imputed and summary estimation was done according to Rubin's
rules [13]. An imputation model was built with age, location on the
vulva, lymph node involvement, Breslow thickness and diameter of
the tumour. All p-values were two-sided, and a p-value of <0.05 was
considered statistically significant. Statistical analysis was performed
using SPSS version 25.0 (IBM).
3. Results
3.1. Patients and tumour characteristics
Two-hundred twenty-three cases were assessed for eligibility and
198 cases were included in this study (S2).
The clinical and histopathological characteristics are presented in
Table 1. Median age at diagnosis was 72 years (IQR 61–78). In most
Table 1
Clinical and histological characteristics.
Clinical characteristics N = 198 (%)

















Stage IA 7 (3.5)
Stage IB 11 (5.6)
Stage IIA 11 (5.6)
Stage IIB 43 (21.7)
Stage IIC 78 (39.4)
Stage III 24 (12.1)
Stage IV 16 (8.1)
Unknown 8 (4.0)
Breslow thickness (median) [mm, IQR] 7.0 [3;14]
Tumour size (median) [mm, IQR] 20.0 [10;30]
Melanoma subtype


























Not analysed 155 (78.3)
Analysed 43 (21.7)
No mutation 29 (67.4)a
BRAF 2 (4.7)a
KIT 7 (16.3)a














Median time to first recurrence [months, IQR] 11 [6,25]
Location of second recurrence (n = 57)
Table 1 (continued)





Median time from first to second recurrence (months) 8 [4,16]
a Of the analysed patients.
b Of the surgically treated patients
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cases (156 of 198, 78.8%), the main symptoms were bleeding, pain, or
pruritis. The interval between first signs and diagnosis ranged from 1
to 55 months, with a median of 4 months. Of the overall study group,
150 (75.8%) patients were diagnosed with clinically localized disease
(AJCC stage IA-IIC), 24 (12.1%) with regional disease (AJCC stage III),
and 16 (8.1%) with distant disease (AJCC stage IV), and in 8 (4.0%) the
stage of disease was undetermined.
The majority of the patients (58.6%) presented with stage T4
(i.e., thickness > 4 mm) tumours. The most common tumour types
were superficial spreading melanoma (SSM) (n = 73; 36.9%) and
nodular malignant (NM) melanoma (n = 71; 35.9%). The median
tumour thickness was 7 mm (IQR 3–14) and the median tumour
size 20 mm (IQR 10–30). Ulceration and mitosis were present in
132 (66.7%) and 120 (60.7%) of the cases. Angiolymphatic involve-
ment, regressive changes, and microsatellosis were reported in the
minority of the tumours. Mutational analysis was performed in
only 43 of the 198 patients (22%). The frequency increased from
8% to 42% in patients diagnosed between 1990 and 2009 and
2010–2017 (Table 1, S3). In 67.4% of the tumours analysed, no po-
tentially targetable mutation was found. KIT mutations were most
frequently detected (18.6%), followed by mutations in BRAF (7%)
and NRAS (4.7%).
Themajority of patients (n=180; 90.9%) underwent primary surgi-
cal resection with curative intent (Table 2). 128 of 180 (71.1%) of these
patients had negative histological margins whereas in 37 (20.6%) pa-
tients the resection margins were positive; in the remaining 15 (8.3%)
the margin status was unknown. Re-excision was performed in 65
(36.1%) of the patients of which 18 had positive margins and 47 had
close margins (data not shown).
In 74 patients (37.4%) nodal surgery was performed at the same
time of the local treatment. Sentinel lymph node (SLN) biopsy was per-
formed in 49 patients (27.2%), and 10 (5.6%) patients had a SLN subse-
quently followed by a full inguinofemoral lymphadenectomy (IFL).
Twenty-one patients (11.7%) underwent an elective IFL and 4 (2.2%) pa-
tients had lymph node dissection.
Adjuvant treatment was given in 15 of 180 (8.3%) patients after
primary surgery. Seven women received local radiotherapy on the
vulva, three women radiotherapy on the groin(s) and three women
both local and groin radiotherapy. Two patients were treated with
systemic therapy of which one with chemotherapy and one with im-
munotherapy (Pembrolizumab). The clinical and histopathological
characteristics of patients diagnosed between 1990 and 2009 did
not significantly differ compared to patients diagnosed between
2010 and 2017, although the latter had slightly more patients with
stage III/IV disease (S3). In addition, patients diagnosed between
2010 and 2017 underwent more often a SLN biopsy and palliative
treatment (S4).
Recurrenceswere treatedwithmany different treatmentmodalities
(S5). Local recurrenceswere primarily treatedwith local surgery, either
aloneor combinedwith local radiotherapy.Themost commontreatment
ofa regional recurrencewaseitheranIFLaloneorcombinationof IFLwith
radiotherapy. Treatment of locoregional recurrences varied greatly and
were often a combination of therapies. Themost common treatment of
distant metastatic diseasewas symptomatic treatment, with palliative
Table 2
Treatment characteristics.
Treatment characteristics N = 198 (%)
Treatment modality
Surgery 165 (83.3)
Surgery plus adjuvant therapy 15 (7.6)
Other 9 (4.5)
Radiotherapy of vulva 3 (1.5)
Radiotherapy of vulva + immunotherapy 1 (0.5)
Radiotherapy of metastasis 1 (0.5)
Neoadjuvant immunotherapy + palliative resection 1 (0.5)
Elective lymph node dissection 1 (0.5)
Immunotherapy 2 (1.0)
Unknown 3 (1.5)
No treatment 6 (3.0)
Type of surgical treatment of primary tumour (n = 180)
Wide local excision 156 (78.8)
Hemivulvectomy 11 (5.6)
Radical vulvectomy 8 (4.1)




Not assessed 93 (47.0)
Lymph node treatment
Not conducted 88 (48.9)
SLN 49 (27.2)
SLN + IFL 10 (5.6)
IFL 21 (11.7)





< 10 mm 64 (35.5)
≥ 10 mm 30(16.7)
< 2 mm 7 (3.9)
≥ 2 mm 87 (48.3)







a Pathologically or radiologically confirmed
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(27%)with distantmetastases received immunotherapy.
3.2. Clinical outcomes
Clinical follow-upranged from1to272months(median31months),
with141deathsat the timeof data collection. Threepatientswere lost to
follow up.
A recurrence occurred in 120 (66.7%) of the surgically treated pa-
tients, at a median of 11 months (IQR 6–25 months) (Table 1). Location
of the first recurrence was local, regional, locoregional or distant in re-
spectively 35.1%, 14%, 21.9% and 29%, suggesting occult metastasis at
time of primary surgery in the majority of the patients. A second recur-
rence occurred in 57 of 120 patients at a median of 8 months. The sec-
ond recurrence was local in 7 patients, regional in 3, locoregional in 2
and distant in 45 patients (78.9%, 95% CI 68.4–89.5).
The estimated median OS for patients diagnosed with VM was 33
months (95% CI 25–40). Estimated cumulative OS was 48% (95% CI
40–56%) at 2 years, 31% (95% CI 23–39%) at 5 years and continued to
fall, to 9% (95% CI 3–15%), at 10 years (Fig. 1A). The estimated RFS for
the overall cohort was 41% (95% CI 33–49%), 26% (95% CI 18–34%) and
16% (95% CI 6–26%) at respectively 2, 5 and 10 years (Fig. 1B). The esti-
mated median survival from recurrence to death for patients with any
recurrence was 10 months (local 15 months, locoregional 16 months,
distant 6 months).4
3.3. Treatment with targeted therapy and checkpoint inhibitors
Twenty-eight patients were treated with immune- or targeted ther-
apy. (Table 3). Five patientswith stage IV disease or irresectable stage III
disease received immunotherapy as primary treatment and 23 patients
were treated with immunotherapy for recurrent disease.
Twenty-four of 28 patients received checkpoint inhibitors of which
eleven (45.8%) had anti PD-1, eight (33.3%) had anti-CTLA-4 and five
(20.9%) had a combination of both. Seven patients were treated with
interferon-alpha or interleukin-2 ofwhich4 combinedwith chemother-
apy. Six patients received targeted therapy of whom three a KIT inhibi-
tor, one a BRAF inhibitor, one with a MEK inhibitor (AZD6244) and one
with a combination of a BRAF and MEK inhibitor.
The estimated median survival after start of immune- or targeted
therapy was 16 months (95% CI 9–23) for patients with immune ther-
apy, 6 months (95% CI 1–10) for targeted therapy and 6 months (95%
CI 5–7) for cytokine therapy with or without chemotherapy.
The outcomes of these therapies have been depicted as Best Overall
Response Rate (BORR, Table 3). Of the 11 patients who received anti-
PD-1 therapy, six had progressive disease (PD), three had stable disease
(SD), one had partial response (PR), and one complete response (CR).
Patients treated with anti-CTLA-4 had PD in 5/8 and SD in 2/8 cases, in
one patient the BORRwasmissing. Of the 5 patients who received com-
bination therapy consisting of anti CTLA-4 and anti PD-1, one had PD,
one had PR, and three had SD. Two patients who were treated with
ipilimumab discontinued their therapy due to toxicity. Of the six pa-
tients treated with targeted therapy, one had PD, two had PR and
three patients had SD.
3.4. Prognostic factors of overall and recurrence-free survival
Survival forpatientsdiagnosedbetween2010and2017didnotsignif-
icantly differ from patients diagnosed between 1990 and 2009 (Fig. 2A).
Prognostic factors for OS and RFS are presented in Table 4 and Fig. 2.
Univariable analysis showed that tumour size, T stage, lymph node in-
volvement, and agewere associatedwithworse OS (Table 4) as well as
the histological variables including mitosis, ulceration, microsatellosis
andangiolymphatic involvement. Lymphnode treatmentwasnot signif-
icantly associatedwithOS(Fig. 2B). Tumour size, T stage, lymphnode in-
volvement and positive resectionmargins were univariably associated
withworseRFS, aswell as thehistological variables includingulceration,
tumour type (other vs SSM), microsatellosis, regressive changes and
angiolymphatic involvement.Patientswithpositivemarginshadasignif-
icantlyworseRFScomparedtopatientswithnegativemargins.Therewas
a trend seen for the association between these factorswithOS, however
thiswas not statistically significant. (Table 4, Fig. 2 CD). T3/T4 stagewas
associated with worse OS and RFS compared to T1/T2 stage disease
(Fig. 2 EF).
Multivariable analysis showed that tumour size and tumour type
(other vs SSM) were significant predictive factors for RFS, whereas age
and tumour size were predictive factors for OS.
4. Discussion
To our knowledge this is the largest series of patients with primary
VM. In this study we show that the prognosis of VM is associated with
high-risk clinicopathological features, including age, tumour thickness,
ulceration, positive resection margins and lymph node involvement.
The 5-year OS and RFS in our cohort was 31% (95% CI 23–39%) and
26% (95% CI 18–34%), respectively. Survival did not improve for patients
diagnosed between 2010 and 2017 compared to patients diagnosed be-
tween 1990 and 2009. Although themajority of patients (75.8%) had lo-
calized disease at diagnosis, two-third of the patients had recurrent
disease with a median survival (from recurrence to death) of 10
months. Overall, the mutation rate in VM was low, although KIT muta-
tions were relatively frequently found.
Fig. 1. Overall survival and recurrence-free survival. A Overall survival B Recurrence-free survival.
Table 3















64 Recurrence distant AZD6244 SD 52 dead 5
65 Primary Vemurafenib PR 10 dead 9
93 Primary Imatinib local radiotherapy SD 8 dead 6
116 Recurrence distant Imatinib PD 21 dead 4
141 Recurrence distant Imatinib local radiotherapy PR 28 dead 16
202 Recurrence distant Dabrafenib + Trametinib SD 36 dead 14
Immune therapy 19 Primary Pembrolizumab wide local excision SD 37 alive 30
22 Recurrence distant Pembrolizumab PD 12 dead 3
35 Recurrence locoregional IFNa PD 83 dead 12
60 Primary Pembrolizumab PD 8 dead 6
61 Recurrence distant Ipilimumab SD 110 dead 25
61 Recurrence distant Nivolumab local radiotherapy SD 110 dead 19
64 Recurrence distant Ticilimumab PD 52 dead 13
65 Primary Ipilimumab unknown 10 dead 2
70 Primary Pembrolizumab palliative resection PD 18 dead 17
70 Primary Pembrolizumab + Ipilimumab PD 18 dead 10
83 Recurrence regional Nivolumab PD 42 alive 8
100 Recurrence distant Nivolumab PR 94 alive 48
124 Recurrence distant Ipilimumab local radiotherapy PD 159 dead 60
124 Recurrence distant Pembrolizumab local radiotherapy CR 159 dead unknown
150 Recurrence distant Cisplatin/DTIC/IL-2/IFNa PD 53 dead 10
188 Recurrence distant Ipilimumab local radiotherapy PD 58 dead unknown
190 Recurrence regional Ipilimumab + nivolumab groin radiotherapy SD 92 alive 21
198 Recurrence distant Pembrolizumab local radiotherapy PD 31 dead 5
198 Recurrence distant Ipilimumab PD 31 dead 1
58 Recurrence distant Ipilimumab + nivolumab SD 35 dead 16
58 Recurrence distant Ipilimumab SD 35 dead 9
67 Recurrence distant Ipilimumab + nivolumab radiotherapy of distant
metastasis
SD 14 unknown 1
133 Recurrence distant IFNa + IL-2 PD 21 dead 6
133 Recurrence distant IFNa, Leiomycin pincrestin +
DTIC
PD 21 dead 3
175 Recurrence distant Temzolomide, GCSF, IL 2 + IFNa local excision metastasis SD 43 dead 6
199 Recurrence distant Ipilimumab + nivolumab PR 39 alive 4
200 Recurrence distant Nivolumab local radiotherapy SD 38 alive 7
202 Recurrence distant Pembrolizumab PD 36 dead 16
162 Recurrence locoregional IFNa Unilateral IFL +
radiotherapy
of the groin
PD 10 dead 5
189 Recurrence distant Ipilimumab PD 24 dead 7
153 Recurrence distant IFNa + IL-2 + DTIC + cisplatin radiotherapy of
distant metastasis
unknown 50 dead 0
9 patients have been treated with two immunotherapeutic strategies of which the second one is underlined.
Drug names: DTIC: Dacarbazine, IL-2: Interleukin 2, IFNa: Interferon Alpha, GCSF: Granulocyte colony-stimulation factor. PD: progressive disease, SD: stable disease, PR: partial response,
CR: complete response.
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Fig. 2. Overall survival by timeframe and nodal treatment and overall and recurrence-free survival by margin status and T stage. A Overall survival by timeframe (1990–2009 vs
2010–2017) B Overall survival by nodal treatment (no treatment vs any type of nodal treatment) C Overall survival by margin status (positive vs < 10 vs ≥ 10) D Recurrence-free
survival by margin status (positive vs < 10 vs ≥ 10) E Overall survival by T stage (T1/2 vs T3/4) F Recurrence-free survival by T stage (T1/2 vs T3/4).
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is wide local excision (WLE) in order to obtain complete resection with
negative margins. [18] Current guidelines for CM recommend surgical
margins of 1–2 cm depending on the tumour thickness. [19] Achieving
thesemargins is often a challenge in VMbecause of anatomical position
close to the clitoris, urethra or anus, and a large proportion of patients
presenting late with locally advanced tumours (i.e., tumour thickness
> 4 mm). In our study, 78% of patients presented with T3/T4 tumours,
and median thickness was 7 mm (Table 1). The majority (71%) of6
surgical resections resulted in negative margins, whereas 21% of the
specimens had positive margins reflecting the challenges surgeons
meet during surgery for VM. Our data showed a statistically significant
difference in RFS but not in OS for patients with positive margins com-
pared to patients with negative margins on primary excision (Table 4,
Fig. 2 CD), as was shown by others. [7] A possible explanation for this
is the increased local recurrence risk with involved margins, which
may not affect the risk for distant recurrence. Importantly, histological
margins of ≥ 10 mm were not statistically associated with better OS
Table 4
Univariable and Multivariable analysis of overall and recurrence-free survival.a
Overall survival n HR (95% CI) p n HR (95% CI) p
Age at diagnosis (per increase of 10 years) 190 1.26 (1.11–1.44) 0.001 171 1.23 (1.06–1.43) 0.005
Location on the vulva
midline vs unilateral 190 1.16 (0.74–1.82) 0.509
multifocal vs unilateral 190 1.32 (0.79–2.21) 0.282
Tumour size (per increase of 1 mm) 190 1.02 (1.01–1.03) <0.001 171 1.02 (1.01–1.03) 0.001
Breslow thickness (per increase of 1 mm) 190 0.99 (0.99–1.01) 0.449
LN involvement (yes vs no) 190 2.10 (1.26–3.48) 0.004 171 1.46 (0.78–2.72) 0.234
Treatment period (2010–2017 vs 1990–2009) 190 0.88 (0.61–1.28) 0.499
Mitosis
yes vs no 190 6.33 (1.56–25.75) 0.010 171 3.29 (0.71–15.12) 0.125
missing vs no 190 5.49 (1.33–22.60) 0.018 171 3.32 (0.73–15.2) 0.122
Ulceration
yes vs no 190 2.46 (1.37–4.38) 0.002 171 1.36 (0.72–2.57) 0.341
missing vs no 190 1.72 (0.88–3.39) 0.114 171 1.07 (0.50–2.32) 0.858
T stage (T3 + T4 vs T1 + T2) 171 2.80 (1.42–5.53) 0.003 171 1.41 (0.65–3.07) 0.381
LN treatment (yes vs no) 169 0.98 (0.69–1.39) 0.904
Tumour type
NM vs SSM 156 1.22 (0.83–1.80) 0.316
other vs SSM 156 1.23 (0.66–2.32) 0.517
Margins (pos vs neg) 165 1.33 (0.87–2.02) 0.190
Margin <2 mm vs ≥ 2 mm 90 1.20 (0.48–3.03) 0.692
Margin <10 mm vs ≥ 10 mm 90 1.24 (0.73–2.12) 0.430
Angiolymphatic involvement (yes vs no) 102 1.91 (1.20–3.04) 0.006
Microsattelosis (yes vs no) 96 3.21 (1.82–5.67) <0.001
Regressive changes (yes vs no) 65 1.17 (0.59–2.31) 0.656
Recurrence-free survival n HR (95% CI) p n HR (95% CI) p
Age at diagnosis (per increase of 10 years) 179 1.03 (0.90–1.17) 0.708
Location on the vulva
midline vs unilateral 179 0.79 (0.47–1.33) 0.370
multifocal vs unilateral 179 1.33 (0.80–2.21) 0.278
Tumour size (per increase of 1 mm) 179 1.02 (1.01–1.03) 0.002 139 1.02 (1.00–1.04) 0.018
Breslow thickness (per increase of 1 mm) 179 1.00 (0.10–1.01) 0.358
LN involvement (yes vs no) 179 1.87 (1.11–3.16) 0.019 139 1.44 (0.73–2.85) 0.290
Treatment period (2010–2017 vs 1990–2009) 179 0.93 (0.63–1.37) 0.698
Ulceration
yes vs no 179 2.71 (1.40–5.25) 0.003 139 1.86 (0.87–3.97) 0.111
missing vs no 179 2.41 (1.16–5.00) 0.019 139 1.99 (0.83–4.77) 0.123
Mitosis
yes vs no 179 2.08 (0.83–5.20) 0.117
missing vs no 179 2.23(0.88–5.66) 0.093
LN treatment (yes vs no) 164 1.13 (0.77–1.65) 0.496
T stage (T3 + T4 vs T1 + T2) 161 2.75 (1.43–5.29) 0.002 139 1.73 (0.78–3.84) 0.178
Tumour type
NM vs SSM 145 1.53 (0.99–2.37) 0.054 139 1.42 (0.88–2.28) 0.149
other vs SSM 145 1.98 (1.05–3.74) 0.035 139 3.15 (1.58–6.31) 0.001
Margins (pos vs neg) 158 1.71 (1.11–2.61) 0.014
Margin <2 mm vs ≥ 2 mm 85 1.30 (0.50–3.35) 0.592
Margin <10 mm vs ≥ 10 mm 85 1.31 (0.73–2.32) 0.363
Microsattelosis (yes vs no) 95 2.10 (1.13–3.87) 0.018
Angiolymphatic involvement (yes vs no) 92 2.60 (1.55–4.36) < 0.001
Regressive changes (yes vs no) 59 3.47 (1.20–5.11) 0.015
Due to more than 50% missing values the variables under the dashed line have only been used for univariable analysis.
Bold values denote statistical significance.
a Univariable analysis and multivariable analysis for OS included respectively 190 and 171 cases with 140 and 125 events. Univariable and multivariable analysis for RFS included re-
spectively 179 and 139 cases with 119 and 92 events. The lower count in in OS and RFS multivariable analysis is due to T stage and tumour type which have not been included in the
imputation.
F.L. Boer, M.L.G. ten Eikelder, N. van Geloven et al. Gynecologic Oncology xxx (xxxx) xxxand RFS compared to margins <10 mm (Table 4, Fig. 2 CD). Also, a his-
tological margin of <2 mm was not statistically associated with worse
OS or RFS (Table 4). Therefore, we recommend that obtaining tumour-
free margins is the primary goal in VM surgery although we did not
find a clear effect of wide negative margins on long-term patient out-
come. This might be due to the highly aggressive nature of the disease,
although a lower available sample sizes for these variables might have
attributed as well.7
SLN biopsy is currently considered the standard nodal assessment
for CM. Since 2005, the preferred approach in patients with CM regard-
ing SLN procedure has very much changed from complete lymphade-
nectomy in case of positive sentinel node to only intervene at the time
positive nodal disease presents clinically. [20–22] No prospective stud-
ies of SLN in VMhave been performed and are unlikely to become avail-
able because of the rarity of the disease. In our study, 49% of the
surgically treated patients underwent groin treatment at the time of
F.L. Boer, M.L.G. ten Eikelder, N. van Geloven et al. Gynecologic Oncology xxx (xxxx) xxxprimary diagnosis, and 27% had SLN procedurewhereas 17% underwent
complete full IFL. Lymph node treatmentwas not associatedwith better
clinical outcomes. This study also shows that despite aggressive primary
surgery in patients with clinically localized disease, still 60% of patients
with VM develop metastatic disease with survival of less than 1 year
(Table 1). Together, these data suggest complete local resection is pref-
erable to radical surgical treatment in VM as vulvar cancer surgery is as-
sociated with serious functional and psychosexual impairment. [23]
As in CM, SLN biopsy in VMmay be used to direct adjuvant therapy
with high-risk disease. Adjuvant treatment is recommended for CM pa-
tients with T4 tumours (with or without ulceration), T3 tumours with
ulceration, or positive lymph nodes because these patients are at high
risk for recurrence. [24,25] Our study shows that most VM patients
have high-risk disease with the majority of patients presenting with
T3 of T4 tumours and/or ulceration (Table 1, Table 4, Fig. 2 EF). Primary
surgery followed by adjuvant radiation therapy has been used to maxi-
mize locoregional control in VM. [26] In our study, only 10 of 180 of pa-
tients received adjuvant radiotherapy. Therefore, we were unable to
unravel the associations of local control and adjuvant radiotherapy,
and thus the use of radiotherapy alongside conservative surgical ap-
proaches requires further study.
Immune checkpoint inhibition (ICI) with anti-CTLA-4 and anti-PD-1
have improved survival for unresectable ormetastatic CM and are now
standardofcareforpatientswithhigh-risk(i.e.,AJCCstageIIIandresected
stage IV) and advanced (i.e., irresectable stage IIIC and IV) CM. [27–30].
Theefficacyof anti-CTLA-4andanti-PD-1antibodieshasnotbeenspecif-
icallyevaluatedin largercohortsofpatientswithMMandprospectivetri-
als in VM have not been performed. Although some studies have
suggested clinical benefit inMM, response rates seem to be lower than
in CM. [10] Subgroup analysis of largemelanoma studies have demon-
strated that ipilimumab (anti-CTLA4) has shown anti-tumour response
in12%of theadvancedMM. [31]Apooledanalysis byd'Angeloet al. eval-
uated nivolumab (anti-PD1) alone (86 patients) or in combinationwith
ipilimumab (35 patients) in unresectable stage III and stage IVMMpa-
tients. [32] The objective response rate (CR or PR) for anti-PD-1mono-
therapywas 23.3%with a progression-free survival (PFS) of 3.0months.
For combination of nivolumab with ipilimumab the response rate was
37.1%withaPFSof5.9months.TheCheckmate238trial includedpatients
withMM(29patients, 3.2%of total) and suggests RFSmaybebetterwith
ipilimumabthannivolumab;however,thisresultwasnotstatisticallysig-
nificantdue to thesmallnumberof patients andevents. [29] Inour study,
the response rate for anti-PD-1 therapy or combination therapy of anti-
PD-1 and anti-CTLA-4was 2/11 (18%) and 1/5 (20%), however, patient
numbers are too small to draw definite conclusions. The suggested
lower response rate ofMM in comparison to CMmight be explained by
the different genomic landscape of MM. Whole genome sequencing
data fromMMdemonstrated a lowmutational burdenwithout any evi-
dence of UV signature, but numerous large-scale copy number changes
andwhole chromosome gains and losses. [3,33] A highmutational bur-
den is associatedwith improved survival in patients receiving ICI across
awidevarietyof cancers, includingmelanoma. [34]Furthermore,den-
sity of tumour infiltrating lymphocytes seems to be decreased inMM
compared to CM, supporting the hypothesis that MM is less immuno-
genic and consequently frequently primarily resistant to ICI. A recent
study has demonstrated a survival benefit of high T-cell infiltration
in a subgroup of patients with VM. [35] To improve the results of ICI
in MM, future alternative or additional treatment strategies aimed at
enhancingthe immunogenicityofMMmaybeof interest. Forexample,
combined radiotherapy and ICI bear the potential to create a synergis-
tic anti-tumour response. [36,37] In addition, the use of oncolytic vi-
ruses has been shown a promising treatment modality in MM.
Talimogene laherparepvec (T-VEC) is a genetically modified herpes
simplexvirus type1andaugments the immunogenicityofmelanomas
by direct oncolytic effects. [38] T-VECwas recently shown to be effec-
tive and well-tolerated in a patient with advanced MM of the urethra
after resistance to ICI. [39]8
The analysis of advanced or metastatic melanomas for alterations
in KIT, NRAS, and BRAF has become standard of care. [19] A recent
study showed that the KIT mutation rate was the highest in VM
(22%) compared with 3% in CM (p < 0.001) and 8.8% in other MM
subtypes (p = 0.05). [14]. In our study, mutations were found in 14
of 43 (32.6%) of analysed tumours with KIT mutations being the
most frequent (18.6%) whereas BRAF, NRAS, GNAQ and Tp53 muta-
tions were rare. (Table 1). A recent study in 73 patients with
unresectable MM, including 8 patients with VM, showed that pa-
tients with KIT-positive tumours had a PFS and OS of 2.7 months
and 11.8 months, compared with 0 and 6.9 months for KIT-negative
tumours, respectively. [40] The differences were not significant due
to small patient numbers.
Themain strength of our study is that this is one of the largest series
that extensively describes the clinical, histopathological and treatment
characteristics in relation to clinical outcome in patients with VM. Of
course, this study has limitations besides its retrospective design. First,
no central histopathologic revision was performed limiting the reliabil-
ity of the histopathological characteristics. Second, our cohort over 27
years in eight different medical centres has resulted in a large but also
heterogeneous dataset.
In summary, VM is an extremely rare malignancy with aggressive
behaviour, which represents a challenge for gynaecological oncologists
and medical oncologists in terms of early diagnosis, clinical and genetic
characterization, and treatment. We would like to emphasise that all
pigmented and nodular vulvar lesions should be considered potentially
harmful in postmenopausal women and deserve to be biopsied in order
to obtain correct diagnosis and implement early treatment. While com-
plete surgical excisionwith negativemargins offers the only prospect of
cure, the challenging anatomical site in VMpresents a high risk of surgi-
cal morbidity and most patients still develop incurable metastatic dis-
ease with survival of less than one year. In contrast to CM, survival did
not show any improvement over the last decade. Increased knowledge
of tumour biology, genetics, and immunemicroenvironmentmay result
in future VM-specific clinical trials focusing on adjuvant therapy in and
therapy for metastatic disease. Specifically, insights into the primary
and metastatic VM immune microenvironment and mechanisms driv-
ing tumour progression, will pave the way for the identification of tar-
gets for future therapies. Therefore, research should be focused on
testing novel promising therapies, and international collaboration in
clinical trials to increase patient numbers is highly needed. This will
hopefully increase the survival benefit of VM patients similarly to
what has recently been observed for CM.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2021.01.018.
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